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Ralph  Steinman,  an  editor  at  the 
Journal  of  Experimental  Medicine 
since  1978,  shared  the  2011  Nobel 
Prize in Physiology or Medicine for his 
discovery of dendritic cells (DCs) and 
their  role  in  immunity.  Ralph  never 
knew. He died of pancreatic cancer 
on September 30, 3 days before the 
Nobel announcement. Unaware of his 
death at the time of their announce-
ment, the Nobel Committee made the 
unprecedented decision that his award 
would stand. Ralph was the consum-
mate  physician-scientist  to  the  end. 
After his diagnosis, he actively partici-
pated in his 4.5 years of treatments, 
creating experimental therapies using 
his own DCs in conjunction with the 
therapies  devised  by  his  physicians, 
all the while traveling, lecturing, and 
most  of  all  pursuing  new  investiga-
tions in his laboratory. For 38 years—
from his discovery of DCs to his Nobel 
Prize—Ralph pioneered the criteria and 
methods used to identify, isolate, grow, 
and study DCs. He and his colleagues 
demonstrated that DCs are initiators 
of immunity and regulators of toler-
ance. In his most recent studies, Ralph 
was  harnessing  the  specialized  fea-
tures of DCs to design improved vac-
cines. The following synopsis describes 
some of his seminal discoveries.
Until Ralph Steinman discovered DCs, 
the innate and adaptive systems had been 
considered separate entities for nearly a 
century. Innate immunity involved Elie 
Metchnikoff’s phagocytes, particularly 
macrophages  that  internalize  and  kill   
microbes. Paul Ehrlich’s adaptive immu-
nity involved lymphocytes that produce 
the antibodies that are so often used 
for clinical benefit. A new dimension to 
Ehrlich’s work was first described in the 
1940s by Merrill Chase, a researcher at 
the Rockefeller Institute who showed 
that lymphocytes, rather than antibodies, 
bring about adaptive immunity. It is 
now  known  that  this  cell-mediated   
immunity involves T lymphocytes in 
many  different  helper,  cytotoxic,  and 
suppressor forms, and that they are all 
controlled  by  DCs.  Ralph’s  discovery 
thus provided the missing link between 
innate and adaptive immunity. DCs are 
essential for understanding how the im-
mune system works during health and 
how  diseases  develop.  They  are  un-
avoidable  targets  for  identifying  new 
preventions and therapies.
Discovery
During his medical training, Ralph was 
challenged  to  learn  how  an  antigen 
provokes an immune response. He rec-
ognized that MacFarlane Burnet’s clonal 
selection theory could not account for 
how the body responds to substances—
both foreign and self—by generating a 
diverse repertoire of immune cells, each 
with a single, distinct antibody as its   
receptor (Burnet, 1957). Because clonal 
selection could not be initiated by add-
ing foreign proteins to lymphocytes,   
it was thought that mysterious “acces-
sory” cells were also required to induce 
immunity. One idea was that accessory 
cells were macrophages.
The story of DCs began in 1970, 
when  Ralph  joined  the  Rockefeller 
University as a postdoctoral fellow in 
the laboratory of Zanvil (Zan) Cohn, 
the  founder  of  modern  macrophage   
biology. This was an ideal place to di-
rectly test whether macrophages would 
trap intact antigens and present them to 
lymphocytes. The laboratory was founded 
by the premier microbiologist René   
Dubos, who recognized the need to study 
the host during infection. He had been 
the ideal mentor for James Hirsch and 
Zan,  two  physicians  devoted  to  infec-
tious disease, who pursued elegant careers 
with  phagocytes.  Dubos,  Hirsch,  and 
Cohn were all editors of this journal.
Ralph’s initial research focused on 
endocytosis of proteins in macrophages. 
But when he was unable to find reser-
voirs of intact antigen on peritoneal 
macrophages, he turned to the spleen to 
see if this organ might harbor cells re-
sponsible  for  generating  immunity 
(Steinman and Cohn, 1972).
Ralph and Zan discovered DCs in 
1973. Looking through a phase contrast 
microscope, they encountered a popula-
tion of cells from the spleen that had 
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between DCs and all other immune cell 
types.  Michel  and  Ralph  used  this 
monoclonal antibody to selectively de-
plete  DCs,  but  not  monocytes,  from 
spleen suspensions to show that the DC 
was the primary stimulator of the MLR 
in bulk spleen (Steinman et al., 1983).
Another student, Wes van Voorhis, 
identified  DCs  in  human  blood   
(Van Voorhis et al., 1982) and devel-
oped a monoclonal antibody that killed 
monocytes, but not DCs. These experi-
ments were important because they pro-
vided evidence that DCs also existed in 
humans and set the stage for later immu-
nization experiments (Inaba et al., 1983).
Ralph  and  Kayo  Inaba  demon-
strated a role for DCs in stimulating   
naive B cells to produce antibodies ca-
pable of binding sheep red blood cells 
and protein antigens. They showed that 
once helper T cells had been activated 
by DCs, the T cells could interact effi-
ciently with antigen-presenting B cells 
to drive B cell clonal expansion and anti-
body production (Inaba and Steinman, 
1984, 1985; Inaba et al., 1984). They 
noted that antigen-reactive T cells clus-
tered on the surfaces of the very small 
number of DCs, typically 1% or less of 
the total cells, in their experimental sys-
tems. Analyzing these T cell–DC clus-
ters, they showed that DCs provide the 
“microenvironment” for T cell activa-
tion and generation of cellular immu-
nity (Inaba et al., 1987).
In all of these systems, small num-
bers of DCs would elicit a T cell re-
sponse, whereas much larger numbers 
of other cell types failed to do so. These 
experiments led to the realization that 
there are two stages to every immune 
response. The first is an afferent stage 
during which DCs stimulate the growth 
and  differentiation  of  rare  quiescent 
precursors  of  antigen-specific  helper 
and cytolytic T cells. The second stage 
is an efferent limb during which T cells 
that have been activated by DCs divide 
in response to encounter with antigens 
that have been processed and presented 
by  other  cells,  including  B  cells  and 
macrophages. This second stage yields 
large numbers of effector T cells that 
participate in many immunological re-
actions  (Steinman  and  Nussenzweig, 
Maggi Witmer-Pack, he evaluated their 
capacity to stimulate the mixed leuko-
cyte reaction (MLR). This T cell reac-
tion had been used for 15 years to detect 
differences in MHC antigens between 
potential donors and recipients of organ 
transplants. At the time, it was termed 
mixed lymphocyte reaction because it 
was thought that B cells from the po-
tential  transplant  donor  triggered  the 
division of T cells of the potential trans-
plant recipient. Ralph showed that the 
newly identified DCs were 100 times 
more potent than bulk spleen cells at 
inciting  the  MLR,  and  that  antigen-
bearing B cells and macrophages con-
tributed little to initiating the reaction. 
The DCs were converting transplanta-
tion antigens into “immunogens” capa-
ble of eliciting cell and organ rejection. 
In  1978,  Ralph  predicted  that  DCs 
would “prove to be a critical accessory 
cell required in the generation of many 
immune  responses”  (Steinman  and 
Witmer, 1978). However, this inter-
pretation was not accepted by most   
immunologists because of the unusual 
features of the MLR in comparison to 
other immune responses. For example, 
the  antigens  responsible  for  initiating 
the MLR were not well defined, and 
vigorous in vitro responses apparently 
required no priming.
Antigen presentation
The next few years were very produc-
tive, and DCs were quickly shown to 
effectively present antigens to T cells. 
Michel Nussenzweig, the first student 
to work on DCs, showed that DCs cap-
ture antigens and present them to cyto-
lytic T lymphocytes. Michel modified 
syngeneic thymocytes with trinitrophe-
nyl and showed that DCs could cap-
ture, process, and present the antigen   
to  produce  MHC-restricted  cytolytic   
T  lymphocytes  (Nussenzweig  et  al., 
1980). Michel also developed 33D1, the 
first DC-specific monoclonal antibody 
(Nussenzweig  et  al.,  1982).  Although 
20 years passed before the antigen rec-
ognized by 33D1 was characterized at 
the  molecular  level  (Dudziak  et  al., 
2007), 33D1 was important because it 
revealed the first molecular distinction 
never  been  seen  before  and  did  not 
look like macrophages. The cells were 
elongated with unusual stellate, or tree-
like,  processes  that  were  constantly 
forming and retracting. Ralph named 
them  dendritic  cells  (from  the  Greek 
word dendreon for tree; Steinman and 
Cohn, 1973, 1974).
Purification
It took nearly 5 years to get pure popu-
lations  of  DCs  and  to  compare  their 
functions with those of other cell types. 
DCs were rare (<1% of mouse spleen 
cells),  and  their  only  unique  markers 
were  their  unusual  shape  and  move-
ment. Fortunately, George Palade, Phil 
Siekevitz,  David  Sabatini,  Günter 
Blobel, and Christian de Duve—who 
were  in  the  process  of  inventing   
modern cell biology—were neighbors 
of the Cohn laboratory in Rockefeller’s 
Bronk Building. The de Duve labora-
tory’s expertise in density gradient cen-
trifugation for subcellular fractionation 
was key to Ralph’s purification meth-
ods.  The  elegant  and  ingenious  steps 
Ralph worked out started with centri-
fuging spleen cells on a bovine serum 
albumin gradient, on which semipuri-
fied DCs rose to the top. He then placed 
this fraction on glass for one hour, deli-
cately washed away all but the DCs and 
some macrophages, and cultured these 
cells overnight to let the DCs detach 
from the culture dish and float into sus-
pension. The lingering few macrophages 
were  removed  by  adding  antibody-
coated sheep red blood cells and centri-
fuging them out (Steinman et al., 1979). 
This procedure was laborious, and the 
DC  yield  was  poor.  As  a  result,  few 
laboratories attempted to reproduce it 
or to work with DCs for many years. 
After  an  antibody  was  developed  to 
CD11c, an antigen expressed by DCs, 
activated  monocytes,  and  NK  cells,   
purification  became  routine  (Metlay   
et al., 1990).
Mixed leukocyte reaction
Functional studies on DCs began once 
Ralph had pure DC populations. He 
noted that DCs expressed high levels of 
MHC proteins. Therefore, along with JEM Vol. 208, No. 12
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of developing monocyte-derived DCs 
in vitro (Trombetta et al., 2003). They 
proposed  that  this  adaptation  allows 
DCs to efficiently capture, process, and 
present  antigens  by  preventing  the 
complete catabolism of protein antigens 
(Inaba et al., 2000). By allowing pep-
tide–MHC II complexes to form inside 
the endocytic system, DCs optimized 
their  subsequent  display  at  the  cell   
surface (Turley et al., 2000). The regu-
lation and composition of the endo-
cytic  system  points  to  a  hallmark 
difference  between  DCs  and  macro-
phages. Whereas macrophages are spe-
cialized for continual antigen scavenging 
and destruction, DCs process antigen in 
a  manner  that  generates  the  peptides 
that bind to different types of antigen- 
presenting molecules.
Ralph’s  studies  with  Michel  on   
endocytic receptors expressed by DCs   
introduced yet another field of study: 
how  to  increase  the  immunogenicity   
of proteins by exploiting specific path-
ways for antigen uptake. The research 
began with biomedical student William   
Swiggard, who isolated DEC-205 (also   
called CD205; Swiggard et al., 1995).   
Wanping Jiang, a postdoctoral fellow in 
Michel’s  laboratory,  cloned  the  gene 
had discovered that Flt-3L, a hemato-
poietin that causes a dramatic 10–15-fold 
expansion  of  DCs  in  mice  and  in   
humans, can be used to grow authentic 
DCs in vitro. Once methods to gener-
ate large numbers of DCs became avail-
able, scientists could more easily study 
their immunizing properties. This de-
velopment triggered a major expansion 
in research and greatly accelerated the 
pace of discovery.
Pursuing the concept that DCs are 
“nature’s  adjuvant,”  Ralph’s  group 
incubated  maturing  DCs  with  anti-
gens in vitro and injected these cells 
into mice and, eventually, humans. The 
DCs  stimulated  T  cell 
growth,  and  the  ex-
panded T cells recognized 
the specific antigens pre-
sented  on  the  MHC 
products of the injected 
DCs (Inaba et al., 1990). 
These  included  micro-
bial  antigens  in  mice   
(Inaba et al., 1993b) and 
model antigens in humans 
(Dhodapkar et al., 1999). 
Prior to these discover-
ies, research on antigen 
presentation had empha-
sized  tissue  culture  sys-
tems and used previously 
activated lymphocytes or 
cloned lymphocyte lines. 
With  DCs,  Ralph  took 
the problem into immu-
nologically  intact  mice 
and humans. By showing 
that  DCs  initiated  im-
munity specific for the 
antigens they had captured, he justified 
using these cells to develop immuno-
therapeutic strategies.
Endocytosis
Ralph  had  assumed  that  splenic  and 
skin  DCs  were  fully  ready  to  initiate 
immunity because of their high content 
of MHC II molecules. But when for-
mer Cohn laboratory member Ira Mell-
man  and  colleagues  at  Yale  brought 
their expertise in cellular molecular bi-
ology to the DC field, they found that 
the MHC II proteins were mostly se-
questered within the endocytic system 
1980; Steinman, 1991). Together, these 
afferent and efferent limbs solve the 
conundrum  of  how  rare  antigen- 
specific  lymphocytes  are  selected  and 
mobilized to bring about vigorous spe-
cific responses.
Maturation
To gain information about DCs in non-
lymphoid tissues, Ralph turned to the 
epidermal Langerhans cells, which were 
also  known  to  express  high  levels  of 
MHC class II proteins. With Gerold 
Schuler,  Niki  Romani,  and  Kayo, 
Ralph  found  that  Langerhans  cells 
needed to differentiate, or mature, to 
become  typical  immune  stimulatory 
cells  (Schuler  and  Steinman,  1985;   
Inaba et al., 1986; Romani et al., 1989). 
Although  Langerhans  cells  were  later 
shown to have a separate cellular origin 
from that of DCs (Merad et al., 2002), 
they served as a model to understand 
DC function. Ralph and his colleagues 
discovered that maturing cells exhibited 
different  functional  attributes  during 
different periods of time. The first func-
tion, antigen capture and presentation, 
is exhibited by immature DCs. The 
second  function,  accessory  or  co- 
stimulatory activity, is mediated by ma-
ture  DCs.  Although  all  DCs  process 
and present antigens, the maturation of 
DCs determines the type and quality of 
the  immune  response  that  will  result 
from  recognition  of  DC-presented   
antigens by T cells. There was also evi-
dence that the environment in which 
DCs mature exerts a major influence on 
the form of adaptive immunity they pro-
mote. Thus, maturation of DCs serves as 
the critical link between innate and adap-
tive T cell–dependent immunity.
Growing DCs
Early research on DCs was limited by 
the  need  to  isolate  these  scarce  cells 
from primary tissues. During the early 
1990s, Ralph and colleagues identified 
methods for stimulating bone marrow 
cells to grow and differentiate in vitro 
into cells that displayed many of the 
phenotypic  characteristics  of  DCs   
(Inaba et al., 1992a,b, 1993a; Romani 
et al., 1994). By 2000, other investigators 
Ralph Steinman. Photo by Robert Reichert, The Rockefeller 
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RNA (poly ICLC) stimulated a broad 
innate immune response mimicking that 
induced by a live viral vaccine.
Ralph  was  that  rare  scientist  who 
lived through a period in which his en-
deavors  came  to  fruition.  He  experi-
enced a revolution in immunology and 
both performed and witnessed work that 
explained how DCs provide the physio-
logical means to initiate clonal expan-
sion, bring about tolerance, differentiate 
lymphocytes into disease-fighting cells, 
and develop memory, each in an anti-
gen-specific manner. Ralph was excited 
when he found novel cells in 1973, and 
he died convinced that these cells had 
become a novel force in medicine.
Carol L. Moberg (moberg@rockefeller.edu) is a 
senior research associate in the Steinman 
laboratory who has written extensively about 
biomedical science. Her biography of René Dubos 
was published by ASM Press in 2006 and her 
history of the pioneering cell biology laboratories 
at the Rockefeller University will be published by 
the Rockefeller University Press in 2012. 
Michel Nussenzweig, Svetlana Mojsov, and 
Maggi Witmer-Pack made valuable contri-
butions to this manuscript.
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Whereas inducing tolerance in fully 
developed  lymphocytes  formerly  re-
quired high doses of nontargeted anti-
gens and met with limited success, the 
targeted  delivery  of  antigen  to  DCs 
more efficiently and specifically silenced 
the immune system.
DC-based vaccines
From the beginning, Ralph planned to 
take DCs into medicine. His deep in-
sights into the biology of DCs and his 
interest in the control of immunity led 
him to explore two novel approaches to 
stimulate innate immunity.
One strategy was an active immuni-
zation against advanced cancer. Madhav 
Dhodapkar,  Ralph,  and  others  devel-
oped ways to remove DCs from a pa-
tient, charge them with specific antigens, 
and deliver them back into the patient 
(Chang et al., 2005). This approach, re-
sulting in expanded and sustained T cell 
responses, recently approved by the US 
Food and Drug Administration, is now 
being used by many other laboratories.
The other vaccine strategy harnesses 
the  major  features  of  DCs—location, 
presentation,  maturation,  and  forma-
tion of subsets—in situ. It involves en-
gineering disease-relevant antigens into 
monoclonal  antibodies  and  targeting 
them to particular DC-specific recep-
tors. This approach, based on the work 
of Hawiger et al. (2001), is currently 
being applied to malaria, tuberculosis, 
Leishmania, cancer, and AIDS. The re-
sulting  T  cell–mediated  immune  re-
sponse to targeted antigens, relative to 
nontargeted antigens, is greater in effi-
cacy, higher in magnitude, and associ-
ated with protection (Boscardin et al., 
2006; Trumpfheller et al., 2006, 2008; 
Nchinda et al., 2008).
A critical and separate issue in target-
ing vaccine proteins is to incorporate a 
stimulus or adjuvant to incite DC matura-
tion. A paper in this issue, by Caskey et al. 
of  the  Rockefeller  Hospital,  together 
with Rafick Sékaly and his colleagues in 
Port  St.  Lucie,  shows  that  in  healthy   
humans  the  adjuvant  double-stranded 
and showed that it encoded an endo-
cytic  receptor,  the  first  such  receptor 
identified on DCs in situ (Jiang et al., 
1995). By incorporating antigens into 
monoclonal antibodies specific for DEC-
205 and administering these antibodies 
to living animals, Daniel Hawiger, a stu-
dent in Michel’s laboratory, first showed 
that targeting antigens to DCs increased 
the  efficiency  of  presentation  by  100-
fold (Hawiger et al., 2001). Although 
the potency of DCs after antigen cap-
ture had been emphasized in the past, 
Ralph and Michel’s work on antigen 
handling revealed that this function of 
DCs can be dramatically improved in 
intact animals.
Immune tolerance
Beginning in 2000, in close collabora-
tion with Michel and Hawiger, Ralph 
uncovered roles for DCs in controlling 
immune tolerance (Hawiger et al., 2001; 
Steinman and Nussenzweig, 2002). To 
analyze tolerance, Ralph took an ap-
proach first suggested by their discovery 
that  immature  DCs  induce  antigen- 
specific tolerance in humans (Dhodapkar 
et al., 2001). Ralph studied two forms 
of antigen. One consisted of peptides 
and proteins incorporated into antibod-
ies that recognize DEC-205, which is 
expressed on DCs in lymphoid tissues 
(Hawiger et al., 2001). The other con-
sisted  of  antigen  within  dying  cells 
(Iyoda et al., 2002; Liu et al., 2002). 
When antigens were attached to anti–
DEC-205, and thus targeted directly to 
immature DCs in vivo, in the absence 
of  inflammatory  stimuli  that  promote 
DC maturation, the antigens were pro-
cessed and recognized by T cells but the 
T cells were tolerized in response. In 
contrast, delivery of a maturation stim-
ulus  together  with  the  same  targeted 
antigen produced long-lived immunity 
involving  both  helper  and  cytolytic   
T  cells  (Hawiger  et  al.,  2001;  Liu   
et al., 2005).
In addition to the classical pathway 
of clonal deletion, the regulatory T cell, 
particularly  the  variety  programmed   
by the protein Foxp3, is a powerful 
mechanism of tolerance. In this issue of   
the journal, a paper by a postdoctoral 
fellow in Ralph’s laboratory (Sela et al.) JEM Vol. 208, No. 12
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